Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD33 Sialic Acid Binding Ig Like Lectin (CD33)
- Target
- CD33
- Molecular classification
- Receptor, Sialic-acid-binding Ig-like lectin (SIGLEC), Immunoglobulin superfamily, Transmembrane protein
01
Overview
CD33 is a transmembrane receptor belonging to the SIGLEC family, predominantly expressed on myeloid cells. It functions as an inhibitory receptor by binding to sialic acid-bearing glycans and recruiting phosphatases via ITIM motifs, thereby dampening immune cell activation. Its high expression in AML makes it a target for antibody-based therapies and CAR-T cell therapy.
- Other names
- Siglec-3SIGLEC3Sialic acid-binding Ig-like lectin 3gp67p67
02
Mechanism of action
Anti-CD33 antibodies bind to CD33, leading to cell death through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct apoptosis induction. Antibody-drug conjugates deliver cytotoxic payload upon internalization. CAR-T cells expressing anti-CD33 chimeric antigen receptors specifically target and kill CD33-expressing cells.
03
Biological functions
Innate immune system regulationRegulation of phagocytosisRegulation of cytotoxicitySignal transductionModulation of immune cell activationApoptosis
04
Disease associations
Acute Myeloid Leukemia (AML)Cardiovascular disease
05
Safety considerations
MyelosuppressionCytokine release syndrome (CRS)Veno-occlusive disease (VOD)Infusion-related reactions
06
Interacting drugs
Anti-CD33 monoclonal antibodies
1 more in the full profile.
07
Biomarkers
CD33 expression level in AML blastsMinimal residual disease (MRD)
Beyond the preview
Go deeper on CD33 Sialic Acid Binding Ig Like Lectin (CD33).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD33 Sialic Acid Binding Ig Like Lectin (CD33).